Reply to Weeks and Sinsheimer

Dalgarno and Sinsheimer

Reply: Subgroup Differences in Response to 8 Weeks of Ledipasvir/Sofosbuvir for Chronic Hepatitis C

Treatment of hepatitis C virus (HCV) infection with ledipasvir/sofosbuvir promises tremendous benefits, but high cost may impede implementation of this regimen. Subgroups with excellent response to 8 weeks of treatment might respond to a shorter course. In ION-3, 423 previously untreated HCV genotype 1-infected patients without cirrhosis had outcome data after receiving ledipasvir/sofosbuvir fo...

The Authors’ Reply

The Authors’ Reply

Reply to Collignon and

TO THE EDITOR—We read with interest the correspondence from Collignon and Kennedy [1] regarding the duration of carriage of resistant bacteria after travelers return from tropical regions. The authors discussed the divergence in duration using a study they published in 2010 [2] and the VOYAG-R study [3]. While the overall design of both studies is similar, some key points are not. Importantly, ...